EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2022

Feb 15, 2013 - GlobalData - 42 pages
Abstract Table of Contents Request Details Related
PRINT & SHARE
Alzheimer's disease is the most common cause of dementia in people age 60 years and older and accounts for approximately 75% of the total dementia cases worldwide (Qui et al., 2009). The global prevalence of dementia is estimated to be 3.9% in people age 60 years and older, with an overall Alzheimer's disease prevalence of 9.7% in the US, 4.4% in Europe, and3.4%in developing countries (Kalaria et al., 2008; Lobo et al., 2000; Plassman et al., 2007). An explosive increase in the number of prevalent cases of Alzheimer's disease in all nine markets is expected during the forecast period. GlobalData epidemiologists forecast that prevalent cases of Alzheimer's disease In the nine major markets (the US, France, Germany, Italy, Spain, the UK, Japan, China, and India) are expected to increase from 12.53 million cases in 2012 to 16.72 million cases in 2022 with an annual growth rate (AGR) of 3.35%. The global burden of the disease is expected to increase due to rapidly aging populations in different parts of the world. Currently, there is no cure for Alzheimer's disease (Mayo Clinic, 2013). Due to the progressive nature of Alzheimer's disease, along with the aging world population, there will be a significant demand for care of persons affected with the disease.

Scope of this Report:
  • The Alzheimer's disease EpiCast Report provides an overview of the risk factors and comorbidities associated with Alzheimer's disease, as well as global trends in prevalence in the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) in addition to emerging markets-China and India).
  • It also includes a 10-year epidemiological forecast of prevalent cases of Alzheimer's segmented by sex and age (segmented by five-year age groups, beginning at age 60 years and ending at =90 years).
Reasons to Get this Report:
  • Develop business strategies by understanding the trends shaping and driving the global Alzheimer's disease market.
  • Quantify patient populations in the global Alzheimer's disease market to improve product development, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying gender and age groups that present the best opportunities for Alzheimer's therapeutics in each of the markets covered.

Order This Report


EASY ORDERING
Once you’ve selected your preferred license option, hit ‘order now’ to complete the checkout process using any major credit card, check or wire/bank transfer.
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.